Form 4 holding
Chief Chemistry Officer
Prelude Therapeutics Inc
- Security class
- Common Stock
- Shares / value
- 480,123
- Estimated value
- $332,485
- Report date
- 25 Mar 2025
- Price
- $0.6925
- Ownership
- Direct
Andrew Combs - Chief Chemistry Officer at Prelude Therapeutics Inc
Issuer-level insider activity
- Role
- Chief Chemistry Officer
- Issuer ticker
- PRLD on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Andrew Combs since 07 Sep 2025
Reported holdings for Andrew Combs in Prelude Therapeutics Inc
Form 4 holding
Chief Chemistry Officer
Prelude Therapeutics Inc
- Security class
- Employee Stock Option (right to buy)
- Shares / value
- 230,000
- Estimated value
- Report date
- 04 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Andrew Combs in Prelude Therapeutics Inc
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.